Upregulated SOX2 expression is correlated with both cisplatin and etoposide resistance in SCLC cell lines, and the signal transducer and activator of transcription 3 (STAT3) inhibitor napabucasin was shown to downregulate SOX2 and MYC, thereby resensitizing cisplatin-resistant cells both in vitro and in vivo (Table 2) [117,158,159]. The gene discussed is MYC; the disease is small cell lung carcinoma.